VBI Vaccines (NASDAQ:VBIV) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 1.5 %

VBI Vaccines stock opened at $0.66 on Friday. The stock has a 50-day moving average price of $0.61 and a 200 day moving average price of $0.61. VBI Vaccines has a 52 week low of $0.45 and a 52 week high of $3.47.

VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.85 million. VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. As a group, equities research analysts expect that VBI Vaccines will post -1.23 earnings per share for the current year.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.